A Drug Above The Rest


Sustained & Self-Clearing,

for Bladder Cancer

and Beyond…

BLADDER CANCER MARKET IS ENORMOUS

Bladder Cancer is Serious, Expensive and Growing

The Market is Moving to Direct Bladder Delivery for Better Outcomes

740k patients with Bladder Cancer

Drug Therapy is $225k/patient/year

$5B peak year sales in US for a successful product

18% CAGR, Worldwide Market

PROGRAMS

Platform Expands Across Bladder Cancer and into Other Markets

Future Indications

  • Small molecule and peptide expansion into each disease state

  • Combination dosing of two
    active agents